someone explain ATTAIN to me like I have not read a paper in years
Asking properly rather than in a comment on somebody else’s thread: someone explain ATTAIN to me like I have not read a paper in years. Went looking for independent testing on this and found essentially nothing, which was clarifying. Compared milligram figures across two completely different molecule classes in a…
What is actually known, and what is being assumed.
Known: it is a small-molecule GLP-1 receptor agonist, dosed daily, with clinical programmes reporting in both obesity and type 2 diabetes. Its tolerability profile broadly resembles the class in the data published so far.
Assumed, frequently and confidently: that milligram comparisons with injectables mean something, that adherence is straightforwardly better because it is a tablet, that peptide purity discussions transfer to it. None of those hold. And nothing containing this compound is approved anywhere, which makes research-use-only material exactly that — not approved for human use.
phase 3 is where the comparison becomes fair
This. The absence of food and water timing restrictions is the practical difference people will actually notice.
Nothing containing this compound is approved by any regulator, and research-use-only material is not approved for human use.
Disagree. You are comparing doses across a small molecule and a peptide, which is not a comparison of anything.
a non-peptide agonist does not degrade the way a peptide does
Daily rather than weekly sounds trivial until you think about what a missed dose means in each case.
Push back: daily dosing is not automatically better adherence. It is a different failure mode, not a solved problem.